Litigation Details for Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Docket		Date Filed	2022-10-28
Court	District Court, D. Delaware	Date Terminated	2024-01-18
Cause	35:1 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,220,042; 11,166,960; 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278
Link to Docket	External link to docket

Details for Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-28				External link to document
2022-10-28	1	Complaint	the ’278 patent”), United States Patent No. 10,220,042 (“the ’042 patent”), United States Patent No. 11,166,960…’898 patent, the ’131 patent, the ’600 patent, the ’930 patent, the ’791 patent, the ’975 patent, the…the ’131 patent”), United States Patent No. 8,617,600 (“the ’600 patent”), United States Patent No. 8,821,930…the ’930 patent”), United States Patent No. 9,119,791 (“the ’791 patent”), United States Patent No. 9,351,975…the ’975 patent”), United States Patent No. 9,370,525 (“the ’525 patent”), United States Patent No. 9,	External link to document

Supernus Pharmaceuticals v. Ajanta Pharma, 1:22-cv-01431: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Supernus Pharmaceuticals sued Ajanta Pharma Limited and related entities in the U.S. District Court for the District of Delaware after receiving notice of an abbreviated new drug application, or ANDA, seeking approval for a generic version of Oxtellar XR, Supernus’s extended-release oxcarbazepine product. The action is an Orange Book patent case involving controlled-release formulation technology. Supernus asserted patents covering Oxtellar XR against Ajanta’s proposed generic product.[1]

The case created a potential barrier to Ajanta’s FDA approval and commercial launch. The central issues were whether Ajanta’s formulation would infringe the asserted claims and whether those claims were valid and enforceable.

What drug and product are involved in Supernus v. Ajanta?

The litigation concerns Oxtellar XR, an extended-release formulation of oxcarbazepine.

Item	Detail
Brand	Oxtellar XR
Active ingredient	Oxcarbazepine
Dosage form	Extended-release oral tablets
Sponsor	Supernus Pharmaceuticals, Inc.
Therapeutic category	Antiepileptic drug
FDA pathway used by challenger	ANDA
Challenger	Ajanta Pharma Limited and affiliated entities
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-01431
Litigation type	Hatch-Waxman patent infringement action

Oxtellar XR is approved for adjunctive therapy in the treatment of partial-onset seizures in adults and children age six and older.[2] Its extended-release delivery system is designed to produce once-daily dosing and reduce peak-to-trough fluctuations compared with immediate-release oxcarbazepine.

Because Ajanta pursued approval through an ANDA, its application necessarily raised patent certification issues under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Supernus filed suit after receiving Ajanta’s Paragraph IV notice.

What patents did Supernus assert against Ajanta?

Supernus’s complaint asserted patents directed to controlled-release oxcarbazepine formulations listed in the FDA Orange Book for Oxtellar XR.[1][3]

The principal patent estate associated with Oxtellar XR includes the following patents:

Patent	General subject matter	Relevance to Oxtellar XR
U.S. Patent No. 8,617,600	Controlled-release oxcarbazepine formulations	Core formulation protection
U.S. Patent No. 9,192,644	Controlled-release oxcarbazepine formulations	Continuation-related formulation claims
U.S. Patent No. 9,980,922	Extended-release oxcarbazepine formulation technology	Later-generation formulation coverage

The asserted claims focus on formulation architecture, release characteristics, excipient selection, and pharmacokinetic performance. The legal analysis therefore depends on the composition and manufacturing details disclosed in Ajanta’s ANDA, not merely on whether both products contain oxcarbazepine.

A generic formulation can avoid literal infringement while still facing a doctrine-of-equivalents theory. The practical outcome usually turns on confidential ANDA materials, expert analysis, dissolution data, and the construction of claim terms describing release rates and dosage-form components.

When does Oxtellar XR lose patent exclusivity?

Oxtellar XR’s exclusivity is governed by several overlapping protections:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents.
3. Patent-term adjustments and extensions.
4. Any settlement restrictions agreed with generic applicants.
5. Unlisted manufacturing or know-how barriers.

The Orange Book remains the primary public source for listed patent information and pediatric exclusivity.[3] Patent expiration dates must be evaluated patent by patent because continuation applications, patent-term adjustments, terminal disclaimers, and patent-term extensions can produce different end dates.

The core Oxtellar XR formulation patents have expiration dates later than the original approval period for the product. That timing made the Ajanta case commercially significant: an adverse judgment could have delayed generic entry for several years, while a successful invalidity or noninfringement defense could have enabled earlier entry after FDA approval.

The case did not involve biologic exclusivity. Oxtellar XR is a small-molecule drug, and Ajanta’s application was an ANDA rather than a biosimilar application under the Biologics Price Competition and Innovation Act.

What was Ajanta’s Paragraph IV challenge?

Ajanta’s Paragraph IV certification represented that the relevant Oxtellar XR patents were invalid, unenforceable, or would not be infringed by the proposed generic product.[1]

A Paragraph IV certification creates a statutory act of infringement under 35 U.S.C. § 271(e)(2). The patent owner can sue before commercial launch, allowing the court to resolve patent disputes before FDA approval or market entry.

For Oxtellar XR, the likely dispute areas included:

• Whether Ajanta’s release profile fell within the asserted claim limitations.
• Whether the generic formulation used the claimed combination of oxcarbazepine and excipients.
• Whether the asserted claims were obvious in view of prior controlled-release antiepileptic formulations.
• Whether the patents were adequately supported by their written descriptions.
• Whether any asserted claims were indefinite.
• Whether Supernus could prove infringement from Ajanta’s ANDA and proposed product.

The filing of a Paragraph IV certification did not itself establish that Ajanta could launch. FDA approval, patent litigation outcomes, settlement terms, and any court-imposed stay remained separate issues.

What litigation events affected Supernus v. Ajanta?

The case was filed in the District of Delaware in 2022 after Ajanta’s ANDA certification. The action followed the standard Hatch-Waxman sequence:

Stage	Significance
ANDA filing by Ajanta	Began the generic approval process
Paragraph IV notice	Challenged listed Oxtellar XR patents
Supernus complaint	Triggered patent litigation under Section 271(e)(2)
30-month stay	Generally blocked FDA approval for the statutory period unless the case was resolved earlier
Claim construction and discovery	Addressed formulation and release-profile issues
Summary judgment or trial	Could determine infringement and validity
Settlement or judgment	Established the practical timing of generic entry

A complete assessment of the litigation requires separating docket status from FDA status. A patent case can be dismissed while FDA review continues. Conversely, an FDA-approved ANDA may remain commercially blocked by patent rights, a settlement agreement, or a launch decision by the generic sponsor.

What is the Orange Book status of Oxtellar XR?

Oxtellar XR is listed in the FDA Orange Book as a prescription drug with patent information submitted by the reference-listing sponsor.[3]

Orange Book listings are commercially important because they determine which patents an ANDA applicant must address. They also influence the availability of a 30-month stay after a Paragraph IV notice.

The Orange Book does not resolve:

• Whether a listed patent is valid.
• Whether the proposed generic infringes.
• Whether the patent is enforceable.
• Whether a settlement permits an earlier launch.
• Whether a generic sponsor will launch at risk.

Those issues are determined through litigation, settlement, or subsequent regulatory and commercial action.

How strong is the Supernus patent estate for Oxtellar XR?

The Oxtellar XR estate has moderate-to-strong commercial value because it is directed to the product’s extended-release formulation rather than only to the active ingredient.

Strengths

The estate’s principal strengths are:

• Product-specific formulation claims.
• Multiple related patents covering controlled-release technology.
• Orange Book listing.
• A formulation that depends on measurable dissolution and pharmacokinetic properties.
• The ability to assert infringement before commercial launch.

Formulation patents can be more durable than compound patents when the active ingredient is old and widely available. They can also make design-around efforts difficult if the commercial product depends on a narrow release profile.

Weaknesses

The principal risks are:

• Prior-art challenges involving controlled-release oxcarbazepine or related antiepileptic products.
• Obviousness attacks based on routine formulation optimization.
• Claim-construction disputes concerning functional release limitations.
• Noninfringement arguments based on different excipients, manufacturing processes, or dissolution profiles.
• Potential invalidity of continuation claims that do not add sufficient patentable subject matter.

Patent strength cannot be assessed solely from the number of Orange Book listings. Claim breadth, prosecution history, terminal disclaimers, prior-art differences, and the actual Ajanta formulation determine the probability of a successful enforcement action.

What generic entry risks existed for Oxtellar XR?

Ajanta faced four principal launch barriers.

Regulatory approval risk

The FDA had to complete its review of Ajanta’s ANDA, including bioequivalence, chemistry, manufacturing, and controls. Patent litigation did not guarantee approval.

Patent-infringement risk

An adverse judgment could have prevented launch until expiration of the asserted patents or another authorized date. A finding of infringement could also expose Ajanta to damages for an at-risk launch.

Settlement restrictions

A settlement could establish an agreed launch date, license terms, or other restrictions. The commercial outcome would depend on the actual agreement rather than the mere dismissal of the case.

Formulation design-around risk

Ajanta could seek a formulation that avoided the asserted claims. That strategy could reduce patent exposure but create additional development, bioequivalence, manufacturing, or regulatory risk.

Did the case involve biosimilars or biologic competition?

No. Supernus v. Ajanta was a small-molecule Hatch-Waxman dispute involving oxcarbazepine. Biosimilar concepts such as reference-product exclusivity, interchangeable designation, and the BPCIA patent dance were not applicable.

The relevant competitive products were generic oxcarbazepine extended-release tablets and other antiepileptic therapies, not biosimilars.

What commercial exposure did the litigation create for Supernus?

Oxtellar XR is one of Supernus’s principal commercial products. A generic launch could affect:

• Oxtellar XR prescription volume.
• Net selling price.
• Rebates and payer positioning.
• Specialty-pharmacy economics.
• Sales-force allocation.
• Revenue forecasts.
• The value of Supernus’s formulation platform.

Generic entry usually produces rapid price erosion, although the pace depends on the number of approved entrants, launch timing, payer substitution, authorized-generic strategy, and the strength of brand loyalty.

Supernus’s exposure was not limited to one patent. A successful challenge to a core formulation patent could influence later generic applicants and weaken the negotiating position in parallel or future settlements.

How does Oxtellar XR’s patent estate compare with Trokendi XR?

Both Oxtellar XR and Trokendi XR are Supernus extended-release antiepileptic products, but they rely on different active ingredients and separate formulation patent estates.

Issue	Oxtellar XR	Trokendi XR
Active ingredient	Oxcarbazepine	Topiramate
Product type	Extended-release tablet	Extended-release capsule
Primary patent issue	Controlled-release oxcarbazepine formulation	Extended-release topiramate formulation
Generic pathway	ANDA	ANDA
Biosimilar risk	None	None
Litigation focus	Release profile and formulation claims	Capsule formulation and controlled-release technology

A favorable result in one product’s litigation would not automatically determine the outcome for the other. The patents, ANDA formulations, claim language, and prior-art records are distinct.

What is the current legal significance of Supernus v. Ajanta?

The case is important as a formulation-patent dispute involving an extended-release antiepileptic product with a substantial commercial base. Its business significance rests on three questions:

1. Whether Ajanta’s ANDA product infringed the asserted Oxtellar XR claims.
2. Whether the asserted claims survived validity challenges.
3. Whether the final resolution imposed a delayed generic launch, permitted an earlier entry, or ended the dispute through a license or settlement.

The case also illustrates the strategic value of Orange Book-listed formulation patents. Even when the active ingredient is off-patent, formulation claims can delay generic competition if they cover the commercial product and withstand invalidity and noninfringement challenges.

Key Takeaways

• Supernus sued Ajanta in Delaware over an ANDA for generic Oxtellar XR.
• The dispute concerned extended-release oxcarbazepine formulation patents.
• The case was a Hatch-Waxman Paragraph IV action, not a biosimilar dispute.
• The relevant patent risks centered on release profiles, excipients, formulation architecture, and obviousness.
• Orange Book listing enabled Supernus to seek pre-launch patent adjudication and a statutory approval stay.
• Generic entry depended on the litigation outcome, FDA approval, and any settlement terms.
• The Oxtellar XR patent estate had commercial value because it protected the extended-release product rather than the already-established oxcarbazepine molecule alone.

FAQs About Supernus Pharmaceuticals v. Ajanta Pharma

What product did Ajanta seek to copy?

Ajanta sought approval for a generic version of Oxtellar XR, Supernus’s extended-release oxcarbazepine product.

Was Supernus v. Ajanta a Paragraph IV lawsuit?

Yes. The action followed Ajanta’s Paragraph IV certification concerning Orange Book-listed Oxtellar XR patents.

Could Ajanta launch before the case ended?

Only if FDA approval was available and Ajanta accepted the risk of an at-risk launch, or if a settlement or court ruling permitted commercial entry.

Were Oxtellar XR’s patents compound patents?

The principal patents at issue were formulation patents directed to controlled-release oxcarbazepine products, rather than basic composition-of-matter patents covering oxcarbazepine itself.

Does this case affect generic Trokendi XR?

No automatic legal effect follows. Trokendi XR contains topiramate and is protected by a separate patent estate, although both products raise similar commercial issues involving extended-release antiepileptic formulations.

References

1. U.S. District Court for the District of Delaware. (2022). Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited et al., No. 1:22-cv-01431. PACER docket and pleadings.

2. U.S. Food and Drug Administration. (n.d.). Oxtellar XR prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,617,600, 9,192,644, and 9,980,922. USPTO.